Cidofovir

The recommended dose of Cidofovir should be administered by intravenous infusion (a drip into a vein). The cidofovir injection must not be administered by other methods including intraocular injection (direct injection into the eye) or topically (on the skin). It should be administered by a healthcare practitioner with apt experience in treating patients with AIDS.

Most common adverse reactions include hair loss, nausea, neutropenia, vomiting, chills, iritis, headache, weakness, fever, decreased intraocular pressure, and uveitis.

• Patients receiving agents with nephrotoxic potential should avoid the use of cidofovir injection. Such agents need to be interrupted at least 7-days prior to initiating cidofovir therapy.
• Close/Precise monitoring of the renal function during cidofovir therapy must be emphasized.
• Patients taking treatment with cidofovir 75 mg/ml vial should be monitored for the neutrophil count.
• Patients should be monitored for the intraocular pressure during therapy with cidofovir.
• Patients need to be monitored for the signs and symptoms of uveitis or iritis while on cidofovir therapy.
• The cidofovir 75 mg injection should not be administered to nursing mothers.
• Women of childbearing potential are advised that cidofovir is embryotoxic and must not be used during pregnancy.
• Patients with hypersensitivity to cidofovir must avoid taking treatment with cidnavir.

Care should be exercised in the handling of CIDNAVIR. CIDNAVIR Injections should not be opened or broken. Store it at controlled room temperature 20 to 25°C (68 to 77°F).

• There is a potential risk that the concomitant therapy of Cidofovir with products containing tenofovir disoproxil fumarate may increase the pharmacodynamic interaction and may increase the risk of Fanconi syndrome.
• The probenecid enhances the AUC of zidovudine. Patients taking treatment with both medicines should be closely assessed for the zidovudine induced haematological toxicity.